• Clarity Pharma announced positive results from Phase 1 trial
  • Starpharma brings VIRALEZE to Indonesia
  • Race Oncology has a new CEO


Clarity Pharma (ASX:CU6) announced that its diagnostic 64Cu SAR-bisPSMA Phase I trial PROPELLER has met all primary and secondary objectives.

Topline results revealed that Cu SAR-bisPSMA is safe and well tolerated in trial participants, and efficacious in the detection of primary prostate cancer.

A dose of 200 megabecquerels (MBq) has been determined as the optimal dose for future trials.

The initial data on will be released at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Symposium in February 2023.

The results will also be used to plan the definitive Phase III clinical trial scheduled to commence in 2023.

The PROPELLER trial was a first-in-human Positron Emission Tomography (PET) imaging trial of participants with prostate cancer using Clarity’s optimised PSMA agent, 64Cu SAR-bisPSMA.

“Being able to accurately stage cancer means that we can better develop a treatment approach that can more effectively prevent its further spread throughout the body,” said Prof Louise Emmett, principal investigator in the PROPELLER trial.


Starpharma goes to Indonesia, while Oncosil woos China

Starpharma (ASX:SPL)‘s VIRALEZE Nasal Spray has been registered in Indonesia, where the company is progressing discussions with potential distribution partners.

The company is also continuing to progress regulatory and commercial activities in multiple other countries, including in markets across Southeast Asia.

“As the largest and most populous country in Southeast Asia, with more than 280 million people, Indonesia represents an exciting market opportunity for Starpharma’s VIRALEZE nasal spray,” said Dr Jackie Fairley, CEO of Starpharma.

Meanwhile Oncosil Medical (ASX:OSL) announced the signing of a distribution agreement for the sale of the OncoSil device in selected Chinese markets.

The agreement with Hind Wing, a company based in Hong Kong SAR, provides exclusive distribution rights for the sale of the OncoSil device within the Hong Kong, Macao, the Greater Bay Area, and the Hainan Special Economic Zone.

Race welcomes new CEO

Race Oncology (ASX:RAC) has appointed Damian Clarke-Bruce as its new CEO, effective 1 February 2023.

Incumbent CEO Phil Lynch will return to his prior role as a non-executive director and will work closely with Clarke-Bruce to ensure a smooth and effective leadership transition.

Dr Tillett meanwhile will continue in his leadership role as chief scientific officer and executive director.

Race says Clarke-Bruce brings deep global experience in drug commercialisation and portfolio strategy.

He has held executive roles at all stages of the drug development process, from pre-clinical evaluation through to successful commercial launch.


Share prices today: